RenovoRx Inc. (RNXT)
NASDAQ: RNXT
· Real-Time Price · USD
1.40
0.01 (0.72%)
At close: Jun 05, 2025, 3:59 PM
0.72% (1D)
Bid | 1.25 |
Market Cap | 51.02M |
Revenue (ttm) | 240K |
Net Income (ttm) | -10.16M |
EPS (ttm) | -0.41 |
PE Ratio (ttm) | -3.4 |
Forward PE | -4.21 |
Analyst | Strong Buy |
Ask | 1.47 |
Volume | 192,134 |
Avg. Volume (20D) | 141,898 |
Open | 1.41 |
Previous Close | 1.39 |
Day's Range | 1.36 - 1.42 |
52-Week Range | 0.75 - 1.69 |
Beta | 1.12 |
About RNXT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol RNXT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for RNXT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
-20.55%
RenovoRx shares are trading lower after the compan...
Unlock content with
Pro Subscription
3 months ago
-2.01%
RenovoRx shares are trading lower after the company announced a proposed public offering.

3 weeks ago · seekingalpha.com
RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call TranscriptRenovoRx, Inc. (NASDAQ:RNXT ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Valter Pinto - IR Ramtin Agah - Founder and Chief Medical Officer Shaun Bagai - CEO Ronald K...

2 months ago · businesswire.com
RenovoRx to Present at LD Micro Invitational XV Conference in New York on April 10thMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing Renov...